Brown Brothers Harriman & CO Biogen Inc. Transaction History

Brown Brothers Harriman & CO

$12.7 Billion
Q2 2024

A detailed history of Brown Brothers Harriman & CO transactions in Biogen Inc. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 5,325 shares of BIIB stock, worth $1.06 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,325

Previous 5,516 3.46%

Holding current value

$1.06 Million

Previous $1.19 Million 3.78%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$190.52 - $236.72 $36,389 - $45,213	-191 Reduced 3.46%	5,325 $1.23 Million
Q1 2024 May 10, 2024	SELL	$212.02 - $267.71 $95,621 - $120,737	-451 Reduced 7.56%	5,516 $1.19 Million
Q2 2023 Aug 07, 2023	SELL	$275.25 - $318.06 $221,025 - $255,402	-803 Reduced 11.86%	5,967 $1.7 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $8,209 - $9,354	32 Added 0.47%	6,770 $1.88 Million
Q4 2022 Feb 09, 2023	BUY	$252.44 - $306.72 $195,388 - $237,401	774 Added 12.98%	6,738 $1.87 Million
Q3 2022 Nov 10, 2022	BUY	$194.69 - $268.46 $5,061 - $6,979	26 Added 0.44%	5,964 $1.59 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $111,030 - $139,892	573 Added 10.68%	5,938 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $118,453 - $152,230	-529 Reduced 8.98%	5,365 $1.29 Million
Q2 2021 Aug 13, 2021	SELL	$259.0 - $414.71 $108,003 - $172,934	-417 Reduced 6.61%	5,894 $2.04 Million
Q1 2021 May 13, 2021	BUY	$242.95 - $284.63 $308,789 - $361,764	1,271 Added 25.22%	6,311 $1.77 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $239,567 - $360,608	1,014 Added 25.19%	5,040 $1.23 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $13,238 - $15,285	-50 Reduced 1.23%	4,026 $1.14 Million
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $72,166 - $95,571	279 Added 7.35%	4,076 $1.09 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $2,957 - $3,751	-11 Reduced 0.29%	3,797 $1.2 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $154,922 - $214,065	-704 Reduced 15.6%	3,808 $1.13 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $178,083 - $199,737	819 Added 22.18%	4,512 $1.05 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $54,822 - $60,430	250 Added 7.26%	3,693 $864,000
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $84,083 - $131,516	388 Added 12.7%	3,443 $814,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $13,925 - $17,637	50 Added 1.66%	3,055 $919,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $22,013 - $28,787	75 Added 2.56%	3,005 $1.06 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $20,086 - $23,938	-78 Reduced 2.59%	2,930 $850,000
Q1 2018 May 14, 2018	SELL	$260.13 - $367.91 $17,688 - $25,017	-68 Reduced 2.21%	3,008 $824,000
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $29,533 - $33,079	96 Added 3.22%	3,076 $980,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $7,872 - $9,231	-28 Reduced 0.93%	2,980 $933,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,008	3,008 $816,000

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.

Account

Brown Brothers Harriman & CO Biogen Inc. Transaction History